Switch theme
Sign up to access all valuation multiples
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
1997
355
LTM Revenue $494M
LTM EBITDA $203M
$3.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zealand Pharma has a last 12-month revenue (LTM) of $494M and a last 12-month EBITDA of $203M.
In the most recent fiscal year, Zealand Pharma achieved revenue of $9.4M and an EBITDA of -$154M.
Zealand Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zealand Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $494M | XXX | $9.4M | XXX | XXX | XXX |
| Gross Profit | $477M | XXX | $8.3M | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | 87% | XXX | XXX | XXX |
| EBITDA | $203M | XXX | -$154M | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | -1633% | XXX | XXX | XXX |
| EBIT | $198M | XXX | -$191M | XXX | XXX | XXX |
| EBIT Margin | 40% | XXX | -2024% | XXX | XXX | XXX |
| Net Profit | $227M | XXX | -$162M | XXX | XXX | XXX |
| Net Margin | 46% | XXX | -1721% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Zealand Pharma's stock price is DKK 454 (or $68).
Zealand Pharma has current market cap of DKK 32.1B (or $4.8B), and EV of DKK 23.9B (or $3.6B).
See Zealand Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.6B | $4.8B | XXX | XXX | XXX | XXX | $2.97 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Zealand Pharma has market cap of $4.8B and EV of $3.6B.
Zealand Pharma's trades at 381.4x EV/Revenue multiple, and -23.4x EV/EBITDA.
Equity research analysts estimate Zealand Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zealand Pharma has a P/E ratio of 21.2x.
See valuation multiples for Zealand Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.8B | XXX | $4.8B | XXX | XXX | XXX |
| EV (current) | $3.6B | XXX | $3.6B | XXX | XXX | XXX |
| EV/Revenue | 7.3x | XXX | 381.4x | XXX | XXX | XXX |
| EV/EBITDA | 17.8x | XXX | -23.4x | XXX | XXX | XXX |
| EV/EBIT | 18.2x | XXX | -18.8x | XXX | XXX | XXX |
| EV/Gross Profit | 7.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.2x | XXX | -29.7x | XXX | XXX | XXX |
| EV/FCF | 17.2x | XXX | -25.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZealand Pharma's last 12 month revenue growth is 85%
Zealand Pharma's revenue per employee in the last FY averaged $27K, while opex per employee averaged $0.6M for the same period.
Zealand Pharma's rule of 40 is -107% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zealand Pharma's rule of X is 253% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zealand Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 85% | XXX | 651% | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | -1633% | XXX | XXX | XXX |
| EBITDA Growth | 141% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -107% | XXX | -1548% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 253% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $27K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 110% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1467% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2112% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zealand Pharma acquired XXX companies to date.
Last acquisition by Zealand Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Zealand Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zealand Pharma founded? | Zealand Pharma was founded in 1997. |
| Where is Zealand Pharma headquartered? | Zealand Pharma is headquartered in Denmark. |
| How many employees does Zealand Pharma have? | As of today, Zealand Pharma has 355 employees. |
| Who is the CEO of Zealand Pharma? | Zealand Pharma's CEO is Mr. Adam Steensberg. |
| Is Zealand Pharma publicy listed? | Yes, Zealand Pharma is a public company listed on CSE. |
| What is the stock symbol of Zealand Pharma? | Zealand Pharma trades under ZEAL ticker. |
| When did Zealand Pharma go public? | Zealand Pharma went public in 2010. |
| Who are competitors of Zealand Pharma? | Similar companies to Zealand Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zealand Pharma? | Zealand Pharma's current market cap is $4.8B |
| What is the current revenue of Zealand Pharma? | Zealand Pharma's last 12 months revenue is $494M. |
| What is the current revenue growth of Zealand Pharma? | Zealand Pharma revenue growth (NTM/LTM) is 85%. |
| What is the current EV/Revenue multiple of Zealand Pharma? | Current revenue multiple of Zealand Pharma is 7.3x. |
| Is Zealand Pharma profitable? | Yes, Zealand Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zealand Pharma? | Zealand Pharma's last 12 months EBITDA is $203M. |
| What is Zealand Pharma's EBITDA margin? | Zealand Pharma's last 12 months EBITDA margin is 41%. |
| What is the current EV/EBITDA multiple of Zealand Pharma? | Current EBITDA multiple of Zealand Pharma is 17.8x. |
| What is the current FCF of Zealand Pharma? | Zealand Pharma's last 12 months FCF is $210M. |
| What is Zealand Pharma's FCF margin? | Zealand Pharma's last 12 months FCF margin is 43%. |
| What is the current EV/FCF multiple of Zealand Pharma? | Current FCF multiple of Zealand Pharma is 17.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
